By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Investigators publish new report on Adenovirus. According to news originating from London, United Kingdom, by NewsRx correspondents, research stated, "Ex vivo gene therapy during coronary artery bypass grafting (CABG) holds great potential to prevent excessive smooth muscle cell (SMC proliferation, neointima formation and graft failure. The most successful preclinical strategies to date have utilised vectors based on the species C adenovirus, Ad5, which engages the Coxsackie and Adenovirus receptor (CAR) as its primary attachment receptor."
Our news journalists obtained a quote from the research from Institute for Women's Health, "Profiling receptors on human SMCs demonstrated the absence of CAR but substantial expression of the species B receptor CD46. We performed transduction experiments using Ad5 and the CD46-utilising adenovirus Ad35, and found Ad35 significantly more efficient at transducing SMCs. To evaluate whether transduction could be further augmented, we evaluated chimeric CD46-utilising Ad5/Ad35 vectors comprising the Ad5 capsid pseudotyped with the Ad35 fibre alone (Ad5/F35) or in combination with the Ad35 penton (Ad5/F35/P35). In human smooth muscle cells (hSMCs), Ad5/F35/P35 mediated significantly higher levels of transduction than either parental vector or Ad5/F35. Ex vivo transduction experiments using mouse aortas from CD46 transgenics demonstrated that Ad5/F35/P35 was significantly more efficient at transducing SMCs than the other vectors tested."
According to the news editors, the research concluded: "Finally, ex vivo transduction and immunofluorescent colocalisation experiments using human tissue from CABG procedures confirmed the preclinical potential of Ad5/F35/P35 as an efficient vector for vascular transduction during CABG."
For more information on this research see: Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction. Gene Therapy, 2013;20(12):1158-1164. Gene Therapy can be contacted at: Nature Publishing Group, Macmillan Building, 4 Crinan St, London N1 9XW, England. (Nature Publishing Group - www.nature.com/; Gene Therapy - www.nature.com/gt/)
The news correspondents report that additional information may be obtained from A.L. Parker, UCL, Inst Womens Hlth, Gene Transfer Technol Grp, London, United Kingdom. Additional authors for this research include K.M. White, C.A. Lavery, J. Custers, S.N. Waddington and A.H. Baker (see also Adenovirus).
Keywords for this news article include: Biotechnology, London, Europe, Adenovirus, Gene Therapy, Muscle Cells, United Kingdom, Bioengineering
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC